aap Implantate AG / Key word(s): Change in Forecast/Profit Warning
27.10.2014 19:48
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
aap updates outlook in view of possible delays in product approvals, U.S.
market entry and project deals
aap Implantate AG announces that possible delays in product approvals and
registrations in Latin America, in gaining U.S. market entry for our
LOQTEQ(R) and trauma product portfolio, and in ongoing project deals may
negatively impact our sales and EBITDA forecast for 2014.
The Management assumes that sales losses directly attributable to the
disposal of equity in the dental joint venture aap BM productions GmbH in
the second quarter of 2014 totaling EUR 1.0 million cannot be compensated
by sales in other business areas. Based on the previous sales forecast for
the fiscal year 2014 of approx. EUR 35 million and taking into account the
aforementioned effect original sales goal amounts to EUR 34 million.
In view of these uncertainties we see for 2014 a target corridor between
EUR 30 million and EUR 34 million for full-year sales and between EUR 2.0
million and EUR 4.5 million for full-year EBITDA (previous forecast:
between EUR 5.0
million and EUR 6.0 million).
The strategic focus of transforming aap Implantate AG into a leading
European trauma enterprise remains our highest priority.
Contact:
aap Implantate AG; Marc Heydrich; Investor Relations; Lorenzweg 5; D-12099
Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290;
m.heydrich@aap.de
27.10.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE0005066609
WKN: 506660
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: aap Implantate AG updates outlook for 2014
| Source: EQS Group AG